Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2020; 10(1):437-461. doi:10.7150/thno.38366 This issue Cite

Review

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Irina Velikyan1✉, Olof Eriksson2

1. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
2. Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden

✉ Corresponding author: Irina Velikyan, Ph.D., Assoc. prof. PET Center, Center for Medical Imaging, Uppsala University Hospital, SE-751 85 Uppsala, Sweden. Tel. +46 (0)70 4834137; Fax. +46 (0)18 6110619; E-mail: irina.velikyanse

Citation:
Velikyan I, Eriksson O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics 2020; 10(1):437-461. doi:10.7150/thno.38366. https://www.thno.org/v10p0437.htm
Other styles

File import instruction

Abstract

Graphic abstract

In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.

Keywords: Exendin-4, insulinoma, GLP-1, diabetes, PET, SPECT

Citation styles

APA
Velikyan, I., Eriksson, O. (2020). Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics, 10(1), 437-461. https://doi.org/10.7150/thno.38366.

ACS
Velikyan, I.; Eriksson, O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics 2020, 10 (1), 437-461. DOI: 10.7150/thno.38366.

NLM
Velikyan I, Eriksson O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics 2020; 10(1):437-461. doi:10.7150/thno.38366. https://www.thno.org/v10p0437.htm

CSE
Velikyan I, Eriksson O. 2020. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics. 10(1):437-461.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use